Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28774593 | 1.00 | ALOX15 (0.67) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL8212959 | 0.89 | ALOX15 (0.75) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL15822302 | 0.83 | ALOX15 (0.67) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL15822299 | 0.83 | ALOX15 (0.67) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL13096525 | 0.83 | ALOX15 (0.67) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL29487266 | 0.83 | ALOX15 (0.67) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL8200730 | 0.83 | ALOX15 (0.67) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| SCHEMBL30472790 | 0.81 | ALOX15 (0.64) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| Linalool SCHEMBL988357 | 0.80 | ALOX15 (1.00) | ALOX15KMT2ACYP3A4MEN1MAPK1 | |
| Linalool SCHEMBL254425 | 0.80 | ALOX15 (1.00) | ALOX15KMT2ACYP3A4MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315976-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2019-06-11 | — | — | US | claimed |
| EP-2920139-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2017-02-01 | — | — | EP | claimed |
| US-20160326082-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2016-11-10 | — | — | US | claimed |
| US-9469590-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2016-10-18 | — | — | US | claimed |
| US-20150307432-A1 | Improvements In or Relating to Organic Compounds | GIVAUDAN S.A. (CH) | 2015-10-29 | — | — | US | claimed |
| EP-0416713-B2 | Process for obtaining aroma components and aromas from their precursors of a glycosidic nature, and aroma components and aromas thereby obtained | DSM NV (NL) | 1999-06-23 | — | — | EP | claimed |
| US-5573926-A | HYDROLYSIS | GIST-BROCADES, N.V. (NL) | 1996-11-12 | — | — | US | claimed |
| WO-1991003174-A1 | PROCESS FOR OBTAINING AROMA COMPONENTS AND AROMAS FROM THEIR PRECURSORS OF A GLYCOSIDIC NATURE, AND AROMA COMPONENTS AND AROMAS THEREBY OBTAINED | GIST-BROCADES N.V. (NL) | 1991-03-21 | — | — | WO | claimed |
| EP-0416713-A1 | Process for obtaining aroma components and aromas from their precursors of a glycosidic nature, and aroma components and aromas thereby obtained | GIST-BROCADES N.V. (NL) | 1991-03-13 | — | — | EP | claimed |
| US-10315976-B2 | Organic compounds | GIVAUDAN S.A. (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20190040417-A1 | BIOLOGICAL FERMENTATION USING DIHYDROXYACETONE AS A SOURCE OF CARBON | KEMBIOTIX LLC (US) | 2019-02-07 | — | — | US | disclosed |
| WO-2017139420-A1 | BIOLOGICAL FERMENTATION USING DIHYDROXYACETONE AS A SOURCE OF CARBON | KEMBIOTIX LLC (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-2920139-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160326082-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2016-11-10 | — | — | US | disclosed |
| WO-2014198709-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-12-18 | — | — | WO | disclosed |
| US-5985618-A | ENZYMATICALLY HYDROLYZING | CIST-BROCADES, N.V. (NL) | 1999-11-16 | — | — | US | disclosed |
| EP-0416713-B2 | Process for obtaining aroma components and aromas from their precursors of a glycosidic nature, and aroma components and aromas thereby obtained | DSM NV (NL) | 1999-06-23 | — | — | EP | disclosed |
| US-5573926-A | HYDROLYSIS | GIST-BROCADES, N.V. (NL) | 1996-11-12 | — | — | US | disclosed |
| WO-1991003174-A1 | PROCESS FOR OBTAINING AROMA COMPONENTS AND AROMAS FROM THEIR PRECURSORS OF A GLYCOSIDIC NATURE, AND AROMA COMPONENTS AND AROMAS THEREBY OBTAINED | GIST-BROCADES N.V. (NL) | 1991-03-21 | — | — | WO | disclosed |
| EP-0416713-A1 | Process for obtaining aroma components and aromas from their precursors of a glycosidic nature, and aroma components and aromas thereby obtained | GIST-BROCADES N.V. (NL) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307432-A1 | Improvements In or Relating to Organic Compounds | CYP11B2, UGT1A9, CYP11B1 | ALOX15 18/4885KMT2A 3270/4885CYP3A4 38/4885 |
| US-20160326082-A1 | Organic Compounds | CYP2C9, UGT1A9, CYP3A4 | ALOX15 66/4885KMT2A 2668/4885CYP3A4 3/4885 |
| US-10315976-B2 | Organic compounds | CYP2C9, UGT1A9, CYP3A4 | ALOX15 66/4885KMT2A 2668/4885CYP3A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.